This EAP is designed to confirm the safety, tolerability, and performance of PET/CT imaging with 89Zr-DFO-girentuximab to non-invasively detect ccRCC in patients with imaging evidence of renal mass(es) at conventional imaging. This protocol is to explore the feasibility of further development of [18F]FTT as a PARP-1 imaging agent. We will conduct prelliminary evaluation of [18F]FTT in men with metastatic prostate cancer. We will evaluate changes in tumor uptake pre and post start of new therapy. Preliminary evaluation of uptake in tumor will evaluate overall imaging quality and collect information about the uptake and retention of [18F]FTT in prostate tumors. Intended management changes between Investigator Survey Questionnaire #1 and #2 represent the impact of imaging findings resulting in intended management changes. The categorization of the management change (major/minor) will be done by the participating site/Investigator and be part of data review plan.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All